Beleaguered drug manufacturer Emergent cuts jobs, executive role in business shake-up

Emergent BioSolutions, the manufacturing company that fell into hot water in 2021 due to a contamination issue involving millions of doses of Covid vaccines, is pivoting its business and cutting hundreds of jobs, including a C-suite role.

The company announced Tuesday that it will cut 400 jobs and eliminate the role of chief operating officer as part of a shift away from its contract manufacturing services business. The current chief operating officer, Adam Havey, will leave the company on Sept. 30.

Instead, Emergent will focus on producing Narcan nasal spray and other products. The overdose reversal medicine became available as an over-the-counter medicine earlier this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In